Literature DB >> 22291083

Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer.

Nadia Harbeck, Achim Rody.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22291083     DOI： 10.1200/JCO.2011.38.9619

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  12 in total

1.  Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer.

Authors:  Alex Farr; Rachel Wuerstlein; Annika Heiduschka; Christian F Singer; Nadia Harbeck
Journal:  Rev Obstet Gynecol       Date:  2013

2.  Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.

Authors:  Roberto A Leon-Ferre; Mei-Yin Polley; Heshan Liu; Judith A Gilbert; Victoria Cafourek; David W Hillman; Ahmed Elkhanany; Margaret Akinhanmi; Jenna Lilyquist; Abigail Thomas; Vivian Negron; Judy C Boughey; Minetta C Liu; James N Ingle; Krishna R Kalari; Fergus J Couch; Daniel W Visscher; Matthew P Goetz
Journal:  Breast Cancer Res Treat       Date:  2017-09-14       Impact factor: 4.872

3.  Measures of outcome in metastatic breast cancer: insights from a real-world scenario.

Authors:  Marta Bonotto; Lorenzo Gerratana; Elena Poletto; Pamela Driol; Manuela Giangreco; Stefania Russo; Alessandro M Minisini; Claudia Andreetta; Mauro Mansutti; Federica E Pisa; Gianpiero Fasola; Fabio Puglisi
Journal:  Oncologist       Date:  2014-05-02

4.  Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?

Authors:  Marta Bonotto; Lorenzo Gerratana; Donatella Iacono; Alessandro Marco Minisini; Karim Rihawi; Gianpiero Fasola; Fabio Puglisi
Journal:  Oncologist       Date:  2015-05-27

Review 5.  [Metastatic breast cancer in the spine : Molecular predictors for choosing adequate treatment strategies].

Authors:  D Adler; M Kriegsmann; P Sinn; A Schneeweiss; H Almansour; B Lehner; M Akbar
Journal:  Orthopade       Date:  2018-07       Impact factor: 1.087

6.  A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors.

Authors:  Jyothi S Prabhu; Aruna Korlimarla; Krisha Desai; Annie Alexander; Rohini Raghavan; Ce Anupama; Nandini Dendukuri; Suraj Manjunath; Marjorrie Correa; N Raman; Anjali Kalamdani; Msn Prasad; K S Gopinath; B S Srinath; T S Sridhar
Journal:  J Cancer       Date:  2014-01-23       Impact factor: 4.207

7.  Life history theory and breast cancer risk: methodological and theoretical challenges: Response to "Is estrogen receptor negative breast cancer risk associated with a fast life history strategy?".

Authors:  Athena Aktipis
Journal:  Evol Med Public Health       Date:  2016-05-21

8.  Racial disparities in survival outcomes among breast cancer patients by molecular subtypes.

Authors:  Fangyuan Zhao; Brenda Copley; Qun Niu; Fang Liu; Julie A Johnson; Thomas Sutton; Galina Khramtsova; Elisabeth Sveen; Toshio F Yoshimatsu; Yonglan Zheng; Abiola Ibraheem; Nora Jaskowiak; Rita Nanda; Gini F Fleming; Olufunmilayo I Olopade; Dezheng Huo
Journal:  Breast Cancer Res Treat       Date:  2020-10-27       Impact factor: 4.872

9.  Dynamic Contrast Enhanced MRI and Intravoxel Incoherent Motion to Identify Molecular Subtypes of Breast Cancer with Different Vascular Normalization Gene Expression.

Authors:  Wan Chen Tsai; Kai Ming Chang; Kuo Jang Kao
Journal:  Korean J Radiol       Date:  2021-05-20       Impact factor: 3.500

10.  Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX.

Authors:  Alan S Coates; Ewan K A Millar; Sandra A O'Toole; Timothy J Molloy; Giuseppe Viale; Aron Goldhirsch; Meredith M Regan; Richard D Gelber; Zhuoxin Sun; Monica Castiglione-Gertsch; Barry Gusterson; Elizabeth A Musgrove; Robert L Sutherland
Journal:  Breast Cancer Res       Date:  2012-11-05       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.